Share ownership Indivior PLC

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:15 2025-07-08 EDT			5-day change	1st Jan Change
1,128.00 ^GBX	-1.48%		+4.06%	+10.16%

09:05am	Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs, Effective July 7, 2025	CI
06-30	Indivior PLC(NasdaqGS:INDV) added to Russell 3000 Value Index	CI

Share class: Indivior PLC

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	124,137,286	119,305,018 ( 96.11 %)	0	96.11 %

Major shareholders: Indivior PLC

Name	Equities	%	Valuation
Two Seas Capital LP 9.676 %	12,072,398	9.676 %	179 M p
Two Seas Capital LP 9.11 %	11,366,777	9.11 %	169 M p
Oaktree Capital Management LP 8.824 %	11,009,125	8.824 %	164 M p
Deerfield Management Co. LP 8.469 %	10,567,160	8.469 %	157 M p
Deerfield Management Co. LP (Private Equity) 8.469 %	10,567,160	8.469 %	157 M p
Oaktree Capital Management LP 7.632 %	9,521,980	7.632 %	141 M p
Goldman Sachs Asset Management LP 6.708 %	8,368,996	6.708 %	124 M p
Goldman Sachs & Co. LLC (Private Banking) 6.486 %	8,092,710	6.486 %	120 M p
Madison Avenue Partners LP 6.245 %	7,792,089	6.245 %	116 M p
Madison Avenue Partners LP 5.962 %	7,438,153	5.962 %	110 M p
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	127.69%
Other	7.02%
Individuals	3.88%
Schweizerische Nationalbank	0.15%
SEI Investments Co.	0.05%
Governments	0.04%
Rathbones Group Plc	0.01%
Manulife Financial Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	117.25%
United Kingdom	7.39%
France	6.36%
Individuals	3.88%
Switzerland	1.85%
Canada	0.61%
Cayman Islands	0.55%
Germany	0.31%
Ireland	0.14%
Singapore	0.05%
Denmark	0.03%
Hong Kong	0.02%
Australia	0.02%
China	0.02%
United Arab Emirates	0.01%
Netherlands	0.01%
Spain	0.01%

Based on 1000 largest holdings

Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.

Employees

1,041

Sector

Pharmaceuticals

Calendar

07-23 - Q2 2025 Earnings Release (Projected)

More about the company